Table 1.

Main features at diagnosis of 22 patients with giant cell arteritis treated with tocilizumab

	GCA patients treated with TCZ (n=22)
Demographic data
Age, years (mean±SD)	72.1±7.0
Female sex, n (%)	14 (63.6)
Weeks from GCA diagnosis to TCZ start, median (range)	58.5 (1–370)
GCA subset
Cranial, n (%)	10 (45.5)
LVV, n (%)	10 (45.5)
Both, n (%)	2 (9)
Cranial manifestations
Temporal headache, n (%)	16 (72.7)
Scalp tenderness, n (%)	9 (40.9)
Jaw claudication, n (%)	10 (45.5)
Visual disturbances, n (%)	13 (59.0)
Amaurosis.	1/13 (7.7)
Blurred vision.	9/13 (69.2)
Diplopia.	3/13 (23.1)
Vision loss, n (%)	6 (27.3)
AION.	3/6 (50.0)
CRAO.	2/6 (33.3)
AION+CRAO.	1/6 (16.7)
Systemic manifestations
PMR symptoms, n (%)	12 (54.5)
Constitutional symptoms, n (%)	18 (81.8)
Fever.	4/18 (22.2)
Night sweats.	14/18 (77.8)
Weight loss.	13/18 (72.2)
Diagnosis confirmatory test
Ultrasound, n (%)	21 (95.4)
Ultrasound alone, n/N (%).	7/21 (33.3)
Ultrasound + PET, n/N (%).	8/21 (38.1)
Ultrasound+TAB, n/N (%).	5/21 (23.8)
Ultrasound+PET+TAB, n/N (%).	1/21 (4.8)
PET/CT alone, n (%)	1 (4.5)
Comorbidities
Hypertension, n (%)	9 (40.9)
Diabetes mellitus, n (%)	5 (22.7)
Osteoporosis, n (%)	3 (13.6)
Patients treated with DMARDs, n (%)	11 (50.0)
Leflunomide, n (%)	6 (27.3)
Mycophenolate mofetil, n (%)	2 (9.1)
Methotrexate, n (%)	4 (18.2)
Azathioprine, n (%)	1 (4.5)

AION, anterior ischaemic optic neuritis; CRAO, central retinal artery occlusion; CT, computed tomography; GCA, giant cell arteritis; LVV, large vessel vasculitis; PET, position emission tomography; PMR, polymyalgia rheumatica; TCZ, tocilizumab.